Mikafungin Pharmazac (Micafungin)

Micafungin, the active ingredient in Mikafungin Pharmazac, is an echinocandin antifungal presented as an intravenous formulation for intravenous use. It treats invasive candidiasis, esophageal candidiasis, and is used for prophylaxis of Candida infections in hematopoietic stem cell transplant recipients.

GNH USA supplies Mikafungin Pharmazac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Micafungin is an echinocandin antifungal indicated for several serious Candida infections.

Invasive candidiasis: effective treatment of bloodstream and deep‑tissue Candida infections. Esophageal candidiasis: resolves mucosal infection in immunocompromised patients. Prophylaxis in hematopoietic stem cell transplant recipients: prevents Candida infection during the high‑risk post‑transplant period.

Micafungin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fever: transient elevation of body temperature. - Chills: shaking sensation during or after infusion. - Nausea: mild gastrointestinal upset. - Elevated liver enzymes: transient increase in ALT/AST. - Headache: mild to moderate intensity. - Infusion‑related erythema: localized skin redness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical intervention. - Severe hepatic dysfunction: marked elevation of liver enzymes or jaundice. - Hypotension: significant drop in blood pressure during infusion. - Seizures: rare neurologic events reported. - Renal failure: acute kidney injury in susceptible patients.

Prior to initiating micafungin therapy, clinicians should consider several safety precautions.

Renal impairment: assess renal function and adjust monitoring as needed. Hepatic impairment: monitor liver function tests regularly. Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant. Concomitant medications: review for possible drug interactions before starting therapy. Infusion administration: administer under medical supervision with appropriate monitoring. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Micafungin can interact with other medicines, affecting its concentration or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may markedly increase micafungin exposure – avoid co‑administration. - Potent CYP3A4 inducers (e.g., rifampin, carbamazepine): can substantially reduce micafungin levels – avoid. - Concurrent use with other echinocandins (e.g., caspofungin, anidulafungin): increased risk of toxicity – avoid.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole, voriconazole): may require liver function monitoring. - Immunosuppressants (e.g., tacrolimus, cyclosporine): monitor drug levels for possible alteration. - Anticoagulants (e.g., warfarin): observe INR for potential changes.